Biocompatible hydrogel treatments for retinal detachment
AssigneeMedical Biosciences LLC
InventorsSyed H. Askari, Yeon S. Choi
Life of this patent
Estimating the term…
Abstract
Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.
Claims14
An in vivo gelling pre-formulation for the treatment of retinal detachment, comprising:
- (a) multi-ARM nucleophilic polyol monomers having more than two nucleophilic arms, wherein each nucleophilic arm comprises a polyethyleneglycol chain and terminates in a nucleophilic group selected from a hydroxyl, thiol, and amino;
- (b) multi-ARM electrophilic polyol monomers having more than two electrophilic arms, wherein each electrophilic arm comprises a polyethyleneglycol chain and terminates in an electrophilic group selected from an epoxide, maleimide, succinimidyl, and an alpha-beta unsaturated ester;
- and
- (c) a viscosity enhancer selected from hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, hydroxypropyl cellulose, carboxymethyl cellulose, sodium hyaluronate, polyvinyl alcohol, and polyvinylpyrrolidone;
- wherein the viscosity of the in vivo gelling pre-formulation is between about 5 cP and 4000 cP;
- and
- wherein the in vivo gelling pre-formulation polymerizes and/or gels at a target site of an eye to form a biocompatible retinal patch.
A method of treating retinal detachment, comprising delivering an in vivo gelling pre-formulation to a site of a retinal tear in a human eye, the in vivo gelling pre-formulation comprising:
- (a) multi-ARM nucleophilic polyol monomers having more than two nucleophilic arms, wherein each nucleophilic arm comprises a polyethyleneglycol chain and terminates in a nucleophilic group selected from a hydroxyl, thiol, and amino;
- (b) multi-ARM electrophilic polyol monomers having more than two electrophilic arms, wherein each electrophilic arm comprises a polyethyleneglycol chain and terminates in an electrophilic group selected from epoxide, maleimide, succinimidyl, and an alpha-beta unsaturated ester;
- and
- (c) a viscosity enhancer selected from hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, hydroxypropyl cellulose, carboxymethyl cellulose, sodium hyaluronate, polyvinyl alcohol, and polyvinylpyrrolidone;
- wherein the viscosity of the in vivo gelling pre-formulation is between about 5 cP and 4000 cP;
- and
- wherein the in vivo gelling pre-formulation polymerizes and/or gels at a target site of an eye to form a biocompatible retinal patch.
Dependencies are inferred from the claim text.